Lifetime Dual Disorder Screening and Treatment Retention: A Pilot Cohort Study
Por:
Puertolas-Gracia, B, Barbaglia, MG, Gotsens, M, Pares-Badell, O, Brugal, MT, Torrens, M, Trevino, L, Rodriguez-Diaz, C, Vazquez-Vazquez, JM, Pascual, A, Coromina-Gimferrer, M, Jimenez-Duenas, M, Oliva, I, Gonzalez, E, Mestre, N, Bartroli, M
Publicada:
1 jul 2022
Resumen:
The coexistence of a substance use disorder and another mental disorder in the same individual has been called dual disorder or dual diagnosis. This study aimed to examine the prevalence of lifetime dual disorder in individuals with alcohol or cocaine use disorder and their retention in treatment. We conducted a pilot cohort study of individuals (n = 1356) with alcohol or cocaine use disorder admitted to treatment in the public outpatient services of Barcelona (Spain) from January 2015 to August 2017 (followed-up until February 2018). Descriptive statistics, Kaplan-Meier survival curves and a multivariable Cox regression model were estimated. The lifetime prevalence of screening positive for dual disorder was 74%. At 1 year of follow-up, >75% of the cohort remained in treatment. On multivariable analysis, the factors associated with treatment dropout were a positive screening for lifetime dual disorder (HR = 1.26; 95% CI = 1.00-1.60), alcohol use (HR = 1.35; 95% CI = 1.04-1.77), polysubstance use (alcohol or cocaine and cannabis use) (HR = 1.60; 95% CI = 1.03-2.49) and living alone (HR = 1.34; 95% CI = 1.04-1.72). Lifetime dual disorder is a prevalent issue among individuals with alcohol or cocaine use disorders and could influence their dropout from treatment in public outpatient drug dependence care centres, along with alcohol use, polysubstance use and social conditions, such as living alone. We need a large-scale study with prolonged follow-up to confirm these preliminary results.
Filiaciones:
Puertolas-Gracia, B:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Inst Hosp Mar Invest Med IMIM, Barcelona 08003, Spain
Univ Pompeu Fabra UPF, Dept Expt & Hlth Sci, Barcelona 08002, Spain
CIBER Epidemiol & Publ Hlth CIBERESP, Madrid 28029, Spain
Barbaglia, MG:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Inst Hosp Mar Invest Med IMIM, Barcelona 08003, Spain
Univ Pompeu Fabra UPF, Dept Expt & Hlth Sci, Barcelona 08002, Spain
IIB St Pau, Biomed Res Inst St Pau, St Antoni Ma Claret 167, Barcelona 08025, Spain
Red Invest Atenc Primaria Adicciones RIAPAd, Madrid 28029, Spain
Gotsens, M:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Pares-Badell, O:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Brugal, MT:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Torrens, M:
Inst Hosp Mar Invest Med IMIM, Barcelona 08003, Spain
Red Invest Atenc Primaria Adicciones RIAPAd, Madrid 28029, Spain
Univ Autonoma Barcelona UAB, Fac Med, Barcelona 08193, Spain
Univ Vic & Catalunya Cent, Fac Med, Barcelona 08500, Spain
Trevino, L:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Rodriguez-Diaz, C:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Vazquez-Vazquez, JM:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Pascual, A:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Coromina-Gimferrer, M:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Jimenez-Duenas, M:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Oliva, I:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Gonzalez, E:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Mestre, N:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Bartroli, M:
Agencia Salut Publ Barcelona, Barcelona 08023, Spain
Green Published, gold
|